Centessa Pharmaceuticals plc ADR [NASDAQ: CNTA] traded at a high on 2025-11-12, posting a 18.46 gain after which it closed the day’ session at $26.7.
The results of the trading session contributed to over 7440045 shares changing hands. Over the past one week, the price volatility of Centessa Pharmaceuticals plc ADR stands at 9.92% while the volatility over the past one month is 7.07%.
The market cap for CNTA stock reached $3.59 billion, with 134.42 million shares outstanding and 85.46 million shares in the current float. Compared to the average trading volume of 1.30M shares, CNTA reached a trading volume of 7440045 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Centessa Pharmaceuticals plc ADR [CNTA]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CNTA shares is $34.31 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CNTA stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Stephens have made an estimate for Centessa Pharmaceuticals plc ADR shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on October 28, 2025. While these analysts kept the previous recommendation, Wells Fargo raised their target price to Overweight. The new note on the price target was released on September 03, 2025, representing the official price target for Centessa Pharmaceuticals plc ADR stock. Previously, the target price had yet another raise to $40, while Oppenheimer analysts kept a Outperform rating on CNTA stock.
The Price to Book ratio for the last quarter was 11.90, with the Price to Cash per share for the same quarter was set at 1.83.
How has CNTA stock performed recently?
Centessa Pharmaceuticals plc ADR [CNTA] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 18.56. With this latest performance, CNTA shares gained by 19.14% in over the last four-week period, additionally plugging by 117.60% over the last 6 months – not to mention a rise of 59.40% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CNTA stock in for the last two-week period is set at 67.67, with the RSI for the last a single of trading hit 2.01, and the three-weeks RSI is set at 1.55 for Centessa Pharmaceuticals plc ADR [CNTA]. The present Moving Average for the last 50 days of trading for this stock 22.73, while it was recorded at 23.31 for the last single week of trading, and 16.76 for the last 200 days.
Centessa Pharmaceuticals plc ADR [CNTA]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Centessa Pharmaceuticals plc ADR [CNTA] shares currently have an operating margin of -1418.22% and a Gross Margin at 93.96%. Centessa Pharmaceuticals plc ADR’s Net Margin is presently recorded at -1607.38%.
Centessa Pharmaceuticals plc ADR (CNTA) Capital Structure & Debt Analysis
According to recent financial data for Centessa Pharmaceuticals plc ADR. ( CNTA), the Return on Equity (ROE) stands at -60.45%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -45.75%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Centessa Pharmaceuticals plc ADR’s Return on Invested Capital (ROIC) is -57.74%, showcasing its effectiveness in deploying capital for earnings.
Centessa Pharmaceuticals plc ADR (CNTA) Efficiency & Liquidity Metrics
Based on Centessa Pharmaceuticals plc ADR’s (CNTA) latest financial statements, the Debt-to-Equity Ratio is 0.39%, indicating its reliance on debt financing relative to shareholder equity.
Centessa Pharmaceuticals plc ADR (CNTA) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Centessa Pharmaceuticals plc ADR. (CNTA) effectively leverages its workforce, generating an average of -$3143246.75 per employee. The company’s liquidity position is robust, with a Current Ratio of 10.57% and a Quick Ratio of 10.57%, indicating strong ability to cover short-term liabilities.
Earnings analysis for Centessa Pharmaceuticals plc ADR [CNTA]
With the latest financial reports released by the company, Centessa Pharmaceuticals plc ADR posted -0.58/share EPS, while the average EPS was predicted by analysts to be reported at -0.35/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -0.23. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CNTA. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Centessa Pharmaceuticals plc ADR go to 5.20%.
Insider trade positions for Centessa Pharmaceuticals plc ADR [CNTA]
There are presently around $94.29%, or 94.74%% of CNTA stock, in the hands of institutional investors. The top three institutional holders of CNTA stocks are: MEDICXI VENTURES MANAGEMENT (JERSEY) LTD with ownership of 19.96 million shares, which is approximately 18.233%. GENERAL ATLANTIC, L.P., holding 9.68 million shares of the stock with an approximate value of $$87.43 million in CNTA stocks shares; and GENERAL ATLANTIC, L.P., currently with $$51.6 million in CNTA stock with ownership which is approximately 5.2191%.
